Palatin Technologies provided an update on its clinical programs, strategic priorities, and anticipated milestones. Program Updates and Anticipated Milestones: Dry Eye Disease: MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies; FDA Confirms Protocols and Endpoints; Targeting Enrollment Start in 4Q Calendar Year 2024; Topline Results Anticipated 4Q Calendar Year 2025; Potential Collaboration/Funding Discussions Ongoing. Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist + Glucagon Like Peptide-1: Patient Dosing Commenced 3Q Calendar Year 2024; Topline Results Expected 1Q Calendar Year 2025. Male Sexual Dysfunction: Development and Clinical Program with Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients That Do Not Respond to PDE5i Monotherapy; Pharmacokinetics Study Expected to Start 1Q Calendar Year 2025; Patient Recruitment in Phase 3 Study Anticipated in 2H Calendar Year 2025. Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients; Interim Analysis Readout Expected in 4Q Calendar Year 2024; Topline Results Anticipated 1Q Calendar Year 2025; Potential Collaboration Discussions Ongoing
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTN:
Questions or Comments about the article? Write to editor@tipranks.com